Listed

Acumen Pharmaceuticals, Inc.

ABOSNasdaqCIK 1576885HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$25.8m, Q3 FY2026
Net income−$25.4m, Q3 FY2026
Acumen Pharmaceuticals, Inc., income statement, quarterly
Line itemUnitQ4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Research and development$m13.3Research and development, Q4 FY2023, three months to 2023-12-31$13.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-27, accession 0001576885-25-000049. Derived: 12-month figure less the 9-month figure.Report this figure12.4Research and development, Q1 FY2024, three months to 2024-03-31$12.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0001576885-25-000065.Report this figure19.5Research and development, Q2 FY2024, three months to 2024-06-30$19.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-12, accession 0001576885-25-000093.Report this figure27.2Research and development, Q3 FY2024, three months to 2024-09-30$27.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figure34.6Research and development, Q4 FY2024, three months to 2024-12-31$34.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001628280-26-021413. Derived: 12-month figure less the 9-month figure.Report this figure25.3Research and development, Q1 FY2025, three months to 2025-03-31$25.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure37.1Research and development, Q2 FY2025, three months to 2025-06-30$37.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure22.0Research and development, Q3 FY2025, three months to 2025-09-30$22.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure20.5Research and development, Q4 FY2025, three months to 2025-12-31$20.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001628280-26-021413. Derived: 12-month figure less the 9-month figure.Report this figure16.5Research and development, Q1 FY2026, three months to 2026-03-31$16.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure27.8Research and development, Q2 FY2026, three months to 2026-06-30$27.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure21.1Research and development, Q3 FY2026, three months to 2026-09-30$21.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure
Operating income$m(18.5)Operating income, Q4 FY2023, three months to 2023-12-31−$18.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-27, accession 0001576885-25-000049. Derived: 12-month figure less the 9-month figure.Report this figure(17.8)Operating income, Q1 FY2024, three months to 2024-03-31−$17.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0001576885-25-000065.Report this figure(24.4)Operating income, Q2 FY2024, three months to 2024-06-30−$24.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-12, accession 0001576885-25-000093.Report this figure(32.3)Operating income, Q3 FY2024, three months to 2024-09-30−$32.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figure(39.6)Operating income, Q4 FY2024, three months to 2024-12-31−$39.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001628280-26-021413. Derived: 12-month figure less the 9-month figure.Report this figure(30.4)Operating income, Q1 FY2025, three months to 2025-03-31−$30.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure(41.8)Operating income, Q2 FY2025, three months to 2025-06-30−$41.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure(26.5)Operating income, Q3 FY2025, three months to 2025-09-30−$26.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure(25.2)Operating income, Q4 FY2025, three months to 2025-12-31−$25.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001628280-26-021413. Derived: 12-month figure less the 9-month figure.Report this figure(21.1)Operating income, Q1 FY2026, three months to 2026-03-31−$21.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure(32.6)Operating income, Q2 FY2026, three months to 2026-06-30−$32.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure(25.8)Operating income, Q3 FY2026, three months to 2026-09-30−$25.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure
Interest expense$m0.6Interest expense, Q4 FY2023, three months to 2023-12-31$581.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-03-26, accession 0001576885-24-000047. Derived: 12-month figure less the 9-month figure.Report this figure1.0Interest expense, Q1 FY2024, three months to 2024-03-31$1.0m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-14, accession 0001576885-24-000064.Report this figure1.0Interest expense, Q2 FY2024, three months to 2024-06-30$1.0m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-12, accession 0001576885-25-000093.Report this figure1.0Interest expense, Q3 FY2024, three months to 2024-09-30$1.0m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figure1.0Interest expense, Q4 FY2024, three months to 2024-12-31$1.0m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-26, accession 0001628280-26-021413. Derived: 12-month figure less the 9-month figure.Report this figure1.0Interest expense, Q1 FY2025, three months to 2025-03-31$1.0m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure1.0Interest expense, Q2 FY2025, three months to 2025-06-30$1.0m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure1.1Interest expense, Q3 FY2025, three months to 2025-09-30$1.1m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure1.1Interest expense, Q4 FY2025, three months to 2025-12-31$1.1m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-26, accession 0001628280-26-021413. Derived: 12-month figure less the 9-month figure.Report this figure1.1Interest expense, Q1 FY2026, three months to 2026-03-31$1.1m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure1.1Interest expense, Q2 FY2026, three months to 2026-06-30$1.1m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure1.0Interest expense, Q3 FY2026, three months to 2026-09-30$999.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure
Net income$m(16.5)Net income, Q4 FY2023, three months to 2023-12-31−$16.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-27, accession 0001576885-25-000049. Derived: 12-month figure less the 9-month figure.Report this figure(14.9)Net income, Q1 FY2024, three months to 2024-03-31−$14.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-13, accession 0001576885-25-000065.Report this figure(20.5)Net income, Q2 FY2024, three months to 2024-06-30−$20.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-12, accession 0001576885-25-000093.Report this figure(29.8)Net income, Q3 FY2024, three months to 2024-09-30−$29.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figure(37.2)Net income, Q4 FY2024, three months to 2024-12-31−$37.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001628280-26-021413. Derived: 12-month figure less the 9-month figure.Report this figure(28.8)Net income, Q1 FY2025, three months to 2025-03-31−$28.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure(41.0)Net income, Q2 FY2025, three months to 2025-06-30−$41.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure(26.5)Net income, Q3 FY2025, three months to 2025-09-30−$26.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure(25.1)Net income, Q4 FY2025, three months to 2025-12-31−$25.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001628280-26-021413. Derived: 12-month figure less the 9-month figure.Report this figure(20.7)Net income, Q1 FY2026, three months to 2026-03-31−$20.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure(32.7)Net income, Q2 FY2026, three months to 2026-06-30−$32.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure(25.4)Net income, Q3 FY2026, three months to 2026-09-30−$25.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure
Diluted EPS$ per sharenot reported(0.25)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0001576885-25-000065.Report this figure(0.34)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-12, accession 0001576885-25-000093.Report this figure(0.50)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.50 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figurenot reported(0.48)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure(0.68)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.68 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure(0.44)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figurenot reported(0.33)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure(0.45)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure(0.35)Diluted EPS, Q3 FY2026, three months to 2026-09-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure
Basic EPS$ per sharenot reported(0.25)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0001576885-25-000065.Report this figure(0.34)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-12, accession 0001576885-25-000093.Report this figure(0.50)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.50 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figurenot reported(0.48)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.48 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure(0.68)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.68 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure(0.44)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figurenot reported(0.33)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.33 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure(0.45)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure(0.35)Basic EPS, Q3 FY2026, three months to 2026-09-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure

Balance sheet

Cash and equivalents$53.1m, Q3 FY2026
Long-term debt$5.9m, Q3 FY2026
Shareholders' equity$34.6m, Q3 FY2026
Acumen Pharmaceuticals, Inc., balance sheet, quarterly
Line itemUnitFY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Cash and equivalents$m66.9Cash and equivalents, FY2023, at 2023-12-31$66.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-27, accession 0001576885-25-000049.Report this figure46.9Cash and equivalents, Q1 FY2024, at 2024-03-31$46.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-14, accession 0001576885-24-000064.Report this figure68.0Cash and equivalents, Q2 FY2024, at 2024-06-30$68.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-13, accession 0001576885-24-000092.Report this figure33.2Cash and equivalents, Q3 FY2024, at 2024-09-30$33.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0001576885-24-000098.Report this figure35.6Cash and equivalents, FY2024, at 2024-12-31$35.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-26, accession 0001628280-26-021413.Report this figure30.2Cash and equivalents, Q1 FY2025, at 2025-03-31$30.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0001576885-25-000065.Report this figure36.8Cash and equivalents, Q2 FY2025, at 2025-06-30$36.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-12, accession 0001576885-25-000093.Report this figure46.8Cash and equivalents, Q3 FY2025, at 2025-09-30$46.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figure54.0Cash and equivalents, FY2025, at 2025-12-31$54.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure51.8Cash and equivalents, Q1 FY2026, at 2026-03-31$51.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure59.4Cash and equivalents, Q2 FY2026, at 2026-06-30$59.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure53.1Cash and equivalents, Q3 FY2026, at 2026-09-30$53.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure
Current assets$m247Current assets, FY2023, at 2023-12-31$246.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-27, accession 0001576885-25-000049.Report this figure256Current assets, Q1 FY2024, at 2024-03-31$255.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-14, accession 0001576885-24-000064.Report this figure267Current assets, Q2 FY2024, at 2024-06-30$266.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-13, accession 0001576885-24-000092.Report this figure208Current assets, Q3 FY2024, at 2024-09-30$207.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001576885-24-000098.Report this figure178Current assets, FY2024, at 2024-12-31$178.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-26, accession 0001628280-26-021413.Report this figure155Current assets, Q1 FY2025, at 2025-03-31$154.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0001576885-25-000065.Report this figure148Current assets, Q2 FY2025, at 2025-06-30$148.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-12, accession 0001576885-25-000093.Report this figure132Current assets, Q3 FY2025, at 2025-09-30$132.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figure122Current assets, FY2025, at 2025-12-31$122.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure133Current assets, Q1 FY2026, at 2026-03-31$133.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure116Current assets, Q2 FY2026, at 2026-06-30$115.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure85.1Current assets, Q3 FY2026, at 2026-09-30$85.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure
Total assets$m310Total assets, FY2023, at 2023-12-31$310.1m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-27, accession 0001576885-25-000049.Report this figure301Total assets, Q1 FY2024, at 2024-03-31$301.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-14, accession 0001576885-24-000064.Report this figure289Total assets, Q2 FY2024, at 2024-06-30$288.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-13, accession 0001576885-24-000092.Report this figure267Total assets, Q3 FY2024, at 2024-09-30$267.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001576885-24-000098.Report this figure239Total assets, FY2024, at 2024-12-31$239.0m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-26, accession 0001628280-26-021413.Report this figure204Total assets, Q1 FY2025, at 2025-03-31$204.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0001576885-25-000065.Report this figure172Total assets, Q2 FY2025, at 2025-06-30$171.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-12, accession 0001576885-25-000093.Report this figure142Total assets, Q3 FY2025, at 2025-09-30$142.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figure123Total assets, FY2025, at 2025-12-31$122.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure134Total assets, Q1 FY2026, at 2026-03-31$133.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure116Total assets, Q2 FY2026, at 2026-06-30$116.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure85.6Total assets, Q3 FY2026, at 2026-09-30$85.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure
Current liabilities$m13.0Current liabilities, FY2023, at 2023-12-31$13.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-27, accession 0001576885-25-000049.Report this figure8.5Current liabilities, Q1 FY2024, at 2024-03-31$8.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-14, accession 0001576885-24-000064.Report this figure15.4Current liabilities, Q2 FY2024, at 2024-06-30$15.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-13, accession 0001576885-24-000092.Report this figure19.9Current liabilities, Q3 FY2024, at 2024-09-30$19.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001576885-24-000098.Report this figure27.6Current liabilities, FY2024, at 2024-12-31$27.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-26, accession 0001628280-26-021413.Report this figure19.3Current liabilities, Q1 FY2025, at 2025-03-31$19.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0001576885-25-000065.Report this figure24.9Current liabilities, Q2 FY2025, at 2025-06-30$24.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-12, accession 0001576885-25-000093.Report this figure22.0Current liabilities, Q3 FY2025, at 2025-09-30$22.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figure30.0Current liabilities, FY2025, at 2025-12-31$30.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure29.2Current liabilities, Q1 FY2026, at 2026-03-31$29.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure46.8Current liabilities, Q2 FY2026, at 2026-06-30$46.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure45.1Current liabilities, Q3 FY2026, at 2026-09-30$45.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure
Total liabilities$m43.2Total liabilities, FY2023, at 2023-12-31$43.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-27, accession 0001576885-25-000049.Report this figure38.9Total liabilities, Q1 FY2024, at 2024-03-31$38.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-14, accession 0001576885-24-000064.Report this figure45.0Total liabilities, Q2 FY2024, at 2024-06-30$45.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-13, accession 0001576885-24-000092.Report this figure49.8Total liabilities, Q3 FY2024, at 2024-09-30$49.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0001576885-24-000098.Report this figure57.2Total liabilities, FY2024, at 2024-12-31$57.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-26, accession 0001628280-26-021413.Report this figure49.0Total liabilities, Q1 FY2025, at 2025-03-31$49.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0001576885-25-000065.Report this figure54.8Total liabilities, Q2 FY2025, at 2025-06-30$54.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-12, accession 0001576885-25-000093.Report this figure49.0Total liabilities, Q3 FY2025, at 2025-09-30$49.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figure52.4Total liabilities, FY2025, at 2025-12-31$52.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure46.2Total liabilities, Q1 FY2026, at 2026-03-31$46.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure58.7Total liabilities, Q2 FY2026, at 2026-06-30$58.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure51.0Total liabilities, Q3 FY2026, at 2026-09-30$51.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure
Long-term debt$m29.9Long-term debt, FY2023, at 2023-12-31$29.9m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2025-03-27, accession 0001576885-25-000049.Report this figure30.2Long-term debt, Q1 FY2024, at 2024-03-31$30.2m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-05-14, accession 0001576885-24-000064.Report this figure29.4Long-term debt, Q2 FY2024, at 2024-06-30$29.4m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-08-13, accession 0001576885-24-000092.Report this figure29.7Long-term debt, Q3 FY2024, at 2024-09-30$29.7m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-11-12, accession 0001576885-24-000098.Report this figure29.4Long-term debt, FY2024, at 2024-12-31$29.4m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2026-03-26, accession 0001628280-26-021413.Report this figure29.5Long-term debt, Q1 FY2025, at 2025-03-31$29.5m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-05-13, accession 0001576885-25-000065.Report this figure29.9Long-term debt, Q2 FY2025, at 2025-06-30$29.9m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-08-12, accession 0001576885-25-000093.Report this figure27.1Long-term debt, Q3 FY2025, at 2025-09-30$27.1m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figure22.4Long-term debt, FY2025, at 2025-12-31$22.4m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure16.9Long-term debt, Q1 FY2026, at 2026-03-31$16.9m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure11.9Long-term debt, Q2 FY2026, at 2026-06-30$11.9m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure5.9Long-term debt, Q3 FY2026, at 2026-09-30$5.9m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure
Short-term borrowings$mnot reportednot reportednot reportednot reported0.0Short-term borrowings, FY2024, at 2024-12-31$0. XBRL concept us-gaap:ShortTermBorrowings. 10-K filed 2026-03-26, accession 0001628280-26-021413.Report this figurenot reportednot reported3.6Short-term borrowings, Q3 FY2025, at 2025-09-30$3.6m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figure8.8Short-term borrowings, FY2025, at 2025-12-31$8.8m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure14.1Short-term borrowings, Q1 FY2026, at 2026-03-31$14.1m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure19.7Short-term borrowings, Q2 FY2026, at 2026-06-30$19.7m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure20.4Short-term borrowings, Q3 FY2026, at 2026-09-30$20.4m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure
Shareholders' equity$m267Shareholders' equity, FY2023, at 2023-12-31$267.0m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-26, accession 0001628280-26-021413.Report this figure262Shareholders' equity, Q1 FY2024, at 2024-03-31$262.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-12, accession 0001576885-25-000093.Report this figure244Shareholders' equity, Q2 FY2024, at 2024-06-30$243.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figure217Shareholders' equity, Q3 FY2024, at 2024-09-30$217.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figure182Shareholders' equity, FY2024, at 2024-12-31$181.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure156Shareholders' equity, Q1 FY2025, at 2025-03-31$155.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure117Shareholders' equity, Q2 FY2025, at 2025-06-30$117.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure93.2Shareholders' equity, Q3 FY2025, at 2025-09-30$93.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure70.4Shareholders' equity, FY2025, at 2025-12-31$70.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure87.5Shareholders' equity, Q1 FY2026, at 2026-03-31$87.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure57.3Shareholders' equity, Q2 FY2026, at 2026-06-30$57.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure34.6Shareholders' equity, Q3 FY2026, at 2026-09-30$34.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure

Cash flow

Operating cash flow−$26.7m, Q3 FY2026
Capital expenditure$0, Q3 FY2026
Acumen Pharmaceuticals, Inc., cash flow, quarterly
Line itemUnitQ4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Operating cash flow$m(8.3)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$8.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-27, accession 0001576885-25-000049. Derived: 12-month figure less the 9-month figure.Report this figure(17.9)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$17.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001576885-25-000065.Report this figure(16.5)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$16.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-12, accession 0001576885-25-000093. Derived: 6-month figure less the 3-month figure.Report this figure(24.6)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$24.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001576885-25-000104. Derived: 9-month figure less the 6-month figure.Report this figure(27.2)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$27.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001628280-26-021413. Derived: 12-month figure less the 9-month figure.Report this figure(34.1)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$34.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure(31.8)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$31.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001628280-26-056199. Derived: 6-month figure less the 3-month figure.Report this figure(30.5)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$30.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-26, accession 0001628280-26-067276. Derived: 9-month figure less the 6-month figure.Report this figure(19.1)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$19.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001628280-26-021413. Derived: 12-month figure less the 9-month figure.Report this figure(24.1)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$24.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure(18.1)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$18.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001628280-26-056199. Derived: 6-month figure less the 3-month figure.Report this figure(26.7)Operating cash flow, Q3 FY2026, three months to 2026-09-30−$26.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-26, accession 0001628280-26-067276. Derived: 9-month figure less the 6-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$14.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2025-03-27, accession 0001576885-25-000049. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$11.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-05-13, accession 0001576885-25-000065.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$5.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-08-12, accession 0001576885-25-000093. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-11-12, accession 0001576885-25-000104. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-03-26, accession 0001628280-26-021413. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2025, three months to 2025-03-31$79.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$9.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-08-12, accession 0001628280-26-056199. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-10-26, accession 0001628280-26-067276. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-03-26, accession 0001628280-26-021413. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-08-12, accession 0001628280-26-056199. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2026, three months to 2026-09-30$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-10-26, accession 0001628280-26-067276. Derived: 9-month figure less the 6-month figure.Report this figure

Shares

Diluted shares (weighted)72.32m, Q3 FY2026
Acumen Pharmaceuticals, Inc., shares, quarterly
Line itemUnitQ1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Diluted shares (weighted)m shares41.0Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3141,025,062 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-14, accession 0001576885-24-000064.Report this figure41.0Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3041,025,062 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-13, accession 0001576885-24-000092.Report this figure54.2Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3054,229,630 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0001576885-24-000098.Report this figure59.8Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3159,812,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0001576885-25-000065.Report this figure60.1Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3060,079,778 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-12, accession 0001576885-25-000093.Report this figure60.1Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3060,079,778 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001576885-25-000104.Report this figure60.5Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3160,525,628 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure60.6Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3060,573,425 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure60.6Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3060,573,425 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure63.2Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3163,219,289 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001628280-26-034204.Report this figure72.3Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3072,250,694 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-12, accession 0001628280-26-056199.Report this figure72.3Diluted shares (weighted), Q3 FY2026, three months to 2026-09-3072,321,459 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure

Shares outstanding: 72.33mShares outstanding, period not labelled, at 2026-10-2172,327,320 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-10-26, accession 0001628280-26-067276.Report this figure at Oct 21, 2026, from the cover of the 10-Q filed Oct 26, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 26, 2026, 16:41 ET. Listed shows no prices and gives no investment advice.